PPT1 and hepatocellular carcinoma: A phase 2 study evaluating GNS561 combination with atezolizumab plus bevacizumab is currently recruiting for the first-line treatment of unresectable HCC patients (NCT05448677), with it being the first trial to assess the benefits of the autophagy PPT1 inhibitor with immune therapy.